Medibank share price dips despite dividend boost

The healthcare insurer will pay its biggest final dividend since 2019.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Medibank share price is suffering on Thursday after the company released its earnings for financial year 2022 this morning 
  • While it posted an 11% fall in after-tax profits, it also revealed the highest dividend payment since 2019 
  • Additionally, an analyst reportedly noted the company's outlook was "better than expected" and might help relieve pricing pressure 

The Medibank Private Ltd (ASX: MPL) share price is trading in the red despite the company revealing its highest final dividend since 2019.

Those invested in the company will receive 7.3 cents per share they hold, representing a portion of the $393.9 million full-year after-tax profit posted earlier today.

When combined with the interim dividend of 6.1 cents per share paid in March, this makes Medibank's FY22 annual dividend also the highest since FY19.

The Medibank share price is trading at $3.50 right now, 0.57% lower than its previous close.

For comparison, the S&P/ASX 200 Index (ASX: XJO) is currently down 0.3%.

Let's take a closer look at the latest news from the insurance-focused healthcare company.

Five healthcare workers standing together and smiling.

Image source: Getty Images

Medibank share price slumps on full-year earnings

The Medibank share price is struggling on Thursday following the release of the company's financial year 2022 earnings.

As my Foolish colleague Aaron reported earlier today, Medibank's full-year net profit represented a 10.9% year-over-year (yoy) fall.

Meanwhile, its revenue from external customers lifted 3% yoy to more than $7 billion. Its segment operating profit rose 11.9% to $638 million.

It also expects its underlying claims per policy to grow 2.3% in financial year 2023. That figure has been heralded by analysts.

Barrenjoey analyst Andrew Adams was quoted by The Australian saying such an outlook is "likely better than expected and takes some of the pressure off the need for a step-up in premium rate increases at the next pricing review."

Medibank CEO David Koczkar said: "The pandemic has triggered a new focus on health and wellbeing, which we expect to continue. A record number of Australians continue to take out private health insurance, especially younger customers."

Today's dip included, the Medibank share price is 2% higher than it was at the start of 2022. Though, it has fallen 1% since this time last year.

For comparison, the ASX 200 has dumped 6% year to date and 5% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »